ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1990
No trial phase data available
No trial data available
No trial data available
No approval data available
- The global cosmetovigilance market, valued at $13.47 billion in 2025, is projected to reach $22.04 billion by 2035 with a CAGR of 5.15%, according to SNS Insider. - Pre-marketing services dominated with 56.38% of 2025 revenue, while post-marketing services are expected to grow fastest at a 5.80% CAGR through 2035. - Europe held the largest market share at 34.87% in 2025, while Asia-Pacific is forecast to grow at the highest rate of 6.91% CAGR through 2035. - A two-day cosmetovigilance masterclass scheduled for December 2026 will provide 12 CPD hours covering causality assessments, PIF architecture, signal detection, and regulatory compliance.
- The UK cardiovascular clinical trials market is forecast to grow from USD 507.8 million in 2025 to USD 892.2 million by 2033, reflecting a compound annual growth rate of 7.6%. - The NHS digital infrastructure encompassing approximately 67 million patient records is a key enabler for participant recruitment and real-world evidence generation in cardiovascular trials. - Approximately 7 million people in England live with cardiovascular conditions, with cardiovascular diseases accounting for about 26% of annual deaths, underscoring the urgent need for new interventions. - Novo Nordisk's January 2026 announcement to extend cardiovascular outcome studies in the UK highlights growing industry investment in obesity-related cardiovascular risk mitigation.
- The global pharmacovigilance automation market was valued at USD 2.80 billion in 2025 and is projected to reach USD 5.25 billion by 2035, growing at a CAGR of 6.50%. - Artificial intelligence dominated the technology segment with a 41.30% market share in 2025, while natural language processing is the fastest-growing segment at a CAGR of 13.73%. - North America held the largest regional share at 38.60% in 2025, with the U.S. market alone valued at USD 0.94 billion and over 2 million adverse event reports filed annually into the FDA's FAERS database. - More than 90% of big pharma companies in regulated markets now use digital systems for adverse event reporting, signaling that automation has become an industry standard.
- The global women's clinical trials and CRO market is projected to grow from $9.9 billion in 2026 to $22.3 billion by 2036, at a CAGR of 8.5%. - Growth is driven by rising prevalence of women-predominant conditions, regulatory requirements for sex-specific safety evaluation, and precision medicine adoption. - Decentralized trial models are accelerating enrollment; Lindus Health's hybrid trials leveraged over 30 million EHRs to double enrollment speed versus traditional approaches. - U.S.-China tariff friction is disrupting biospecimen flows and central lab operations, prompting sponsors to shift recruitment toward CRO networks in India, Southeast Asia, and Europe.
- The global imaging CRO services market is projected to grow from $1.83 billion in 2026 to $3.51 billion by 2035, at a CAGR of 7.9%. - Over 90% of oncology trials now utilize imaging to assess tumor response, with centralized review reducing inter-reader variability by nearly 35%. - AI-driven tools are used by 42.6% of leading imaging CROs, yet only 15% of clinical trials use AI as a primary endpoint assessment tool, signaling significant growth potential. - North America leads with a 41% market share, while Asia-Pacific is the fastest-growing region with a 30% cost advantage for clinical research.
- Thermo Fisher Scientific has completed its $8.875 billion acquisition of Clario Holdings, a leading provider of endpoint data solutions for clinical trials, following EU regulatory approval. - Clario's platform has supported approximately 70% of FDA and EMA novel drug approvals over the past decade through its imaging, eCOA, and precision motion technologies. - The acquisition is expected to contribute $0.45 of adjusted earnings per share in the first year and generate approximately $175 million in synergies by year 5. - The combined entity targets high single-digit growth with the deal providing a double-digit internal rate of return for Thermo Fisher.
- The early phase clinical trial outsourcing market is expected to grow from $9.53 billion in 2025 to $14.8 billion by 2030, representing a compound annual growth rate of 9.2%. - Personalized medicine is emerging as a central driver, with personalized therapies for rare diseases more than doubling from 6 in 2022 to 16 in 2023 according to the Personalized Medicine Coalition. - Key growth factors include adoption of decentralized trial methods, precision medicine focus, AI-enabled trial analytics, and increasing complexity of drug development pipelines. - North America currently holds the largest market share, while Asia-Pacific is anticipated to be the fastest-growing region during the forecast period.
- Trellus Health received a six-month contract extension from Johnson & Johnson to continue providing its Trellus Elevate digital platform for inflammatory bowel disease patients through mid-2026. - The extension was granted based on achievement of key engagement and satisfaction metrics during the initial pilot phase, with J&J expanding patient access channels in response to positive performance. - The company is simultaneously scaling its TrialSet platform across multiple clinical trials with major pharmaceutical partners including Takeda and Sanofi through leading CRO partnerships. - Trellus Health's platform has demonstrated significant clinical impact, with IBD patients experiencing over 90% fewer hospitalizations and over 70% reduction in emergency room visits.
- A comprehensive 2025 clinical trials review reveals the current global research landscape for acquired autoimmune hemolytic anemia, analyzing trial data across regions, phases, and sponsor types. - The report identifies prominent pharmaceutical companies including Sanofi, Novartis, AstraZeneca, and Johnson & Johnson as key players conducting trials for this rare hematological disorder. - Analysis covers enrollment trends over five years and provides insights into trial success rates through comparative analysis of completed versus uncompleted studies. - The database compilation from over 80 clinical trial registries worldwide offers strategic intelligence for investment decisions and optimal trial location selection.
- ICON plc achieved the highest sponsor satisfaction score of 7.4 out of 10 for phase 1 clinical trials, outperforming all other large contract research organizations. - The company outperformed competitors in all 17 operational metrics with considerable leads in 14 categories, including delivery timelines, therapeutic expertise, and clinic availability. - ICON demonstrated six consecutive years of superior performance in phase 1 trials, establishing sustained excellence in early-phase clinical development. - The benchmarking report from Industry Standard Research surveyed 159 industry professionals in Q4 2024, highlighting ICON's operational excellence and innovation.
